FDA Inspection 1200327 — Janssen Research & Development

Janssen Research & Development — FEI 3009637192

The FDA completed an inspection of Janssen Research & Development on Mar 1, 2023 in Raritan, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.

Inspection details

Classification
No Action Indicated (NAI)
End Date
Mar 1, 2023
Fiscal Year
2023
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Raritan, NJ (United States)

Additional details

Sponsor, Contract Research Organization

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.